Bringing Polygenics Into Cardiovascular Disease Diagnosis
Effective Tool To Measure Lifetime Risk Of CHD From Polygenics Technology Innovator
GENinCode’s mission as a clinical-genetic diagnostic company is to apply a combination of polygenics, a proprietary bioinformatics platform and AI to risk-assess and prevent cardiovascular disease. The company set a UK precedent in being the first to have a CVD commercial polygenic test implemented in the NHS and keenly awaits another milestone, US 510k clearance in 2024.
You may also be interested in...
UK ministers are increasingly focusing on the need to improve uptake of new technologies in the National Health Service. Ambitious programs have been launched but implementing them effectively for lasting change in a delivery system under acute stress is a challenge of a different order.
3M’s health care company spin-off is expected to be launched in the first half of 2024 under the name Solventum.
A scale-up strategy is the missing link in the UK devices industry, claims business research organization CPI. Own brand and contract medical manufacturer and packaging company Pennine Healthcare and longstanding medical device CDMO Renfrew Group International give their take on the environment for manufacturers and the opportunities for strengthening the industry base.